Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 13,909 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Trial Clear all

Conditions: Premature Pubarche
Interventions: sugar pill, Metformin, glucophage; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 4 Years to 10 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: Indianapolis, Indiana • Hershey, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Endometriosis
Interventions: NettleEndo, Sham NettleEndo Device; Device
Lead sponsor: Samphire Group, Inc.; Industry
Eligibility: 22 Years to 45 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Prostate Cancer Metastatic
Interventions: PROSTVAC-V, PROSTVAC-F, GM-CSF, GM-CSF Placebo, Placebo; Biological · Drug · Other
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 84
States / cities: Anchorage, Alaska • Scottsdale, Arizona • Berkeley, California + 68 more

Conditions: Substance-Related Disorders
Interventions: Rivastigmine; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer
Interventions: Atezolizumab, Trastuzumab Emtansine, Placebo, Trastuzumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2034
U.S. locations: 22
States / cities: Birmingham, Alabama • Buena, California • Santa Monica, California + 19 more

Conditions: Childhood Obesity
Interventions: Newsletters, Family-based Telehealth Intervention; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 5 Years to 11 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Stage III Merkel Cell Carcinoma AJCC v8, Stage IIIB Merkel Cell Carcinoma AJCC v8, Stage IIIA Merkel Cell Carcinoma AJCC v8
Interventions: Avelumab, Peripheral Blood Collection, Placebo; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 9
States / cities: Orange, California • Aurora, Colorado • Tampa, Florida + 6 more

Conditions: Gynecologic Cancers
Interventions: Starting the Conversation, Sexual Health Resources; Behavioral
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pancreatic Diseases
Interventions: Somatostatin analog; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Insomnia, HIV, Aids
Interventions: CBT-I Treatment Condition, SH Comparison Condition; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Atrial Fibrillation, Atrial Flutter
Interventions: Metoprolol, Diltiazem; Drug
Lead sponsor: CAMC Health System; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 1
States / cities: Charleston, West Virginia

Conditions: Nicotine Dependence
Interventions: GSK598809, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Cancer of Breast, Cancer of the Breast
Interventions: Breast-conserving surgery (BCS), Cavity shave margins (CSM), BREAST-Q Questionnaire, 3-D breast imaging, Indocyanine green, Intraoperative imaging device, Peripheral blood draw; Procedure · Behavioral · Device + 1 more
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diabetes Mellitus, Type 2
Interventions: Dulaglutide, Placebo, Insulin Glargine, Metformin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 13
States / cities: Fresno, California • San Mateo, California • Tustin, California + 10 more

Conditions: Breast Cancer
Interventions: 4-hydroxytamoxifen, breast imaging study, radiomammography; Drug · Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 30 Years to 50 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Emphysema
Interventions: Exhale® Drug-Eluting Stent, Sham control; Device
Lead sponsor: Broncus Technologies; Industry
Eligibility: 35 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 26
States / cities: Phoenix, Arizona • Fresno, California • Los Angeles, California + 21 more

Conditions: Schizophrenia
Interventions: Iclepertin, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 20
States / cities: Bellflower, California • Costa Mesa, California • Long Beach, California + 17 more

Conditions: Spinal Cord Injuries
Interventions: Living Longer and Stronger with SCI, Control; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Escherichia Infection
Interventions: B7A (ETEC challenge strain), CssBA, dmLT, Placebo; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Baltimore, Maryland • Cincinnati, Ohio

Conditions: Tumor Hyperinsulinism (Tumor HI)
Interventions: Ersodetug; Drug
Lead sponsor: Rezolute; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: Chicago, Illinois • Bethesda, Maryland • Boston, Massachusetts + 5 more

Conditions: PTSD
Interventions: Renew; Behavioral
Lead sponsor: Palo Alto Veterans Institute for Research; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Menlo Park, California

Conditions: Clinical Trial
Interventions: Family Check-Up 4 Health, Treatment as usual; Behavioral · Other
Lead sponsor: Arizona State University; Other
Eligibility: 6 Years to 12 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 3
States / cities: Phoenix, Arizona

Conditions: Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, Glioblastoma Multiforme, Adult
Interventions: Posaconazole Pill; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Generalized Anxiety Disorder
Interventions: SEP-363856, Placebo; Drug · Other
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 576 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 17
States / cities: Tucson, Arizona • Encino, California • Sherman Oaks, California + 13 more

Search by objective public record fields.

Metformin for the Treatment of Premature Pubarche in Girls

Remote Electrical Stimulation as a Long-term Intervention for Endometriosis Flare Ups

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

Rivastigmine For Methamphetamine Dependent Individuals

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

A Theory Driven, Rurally Tailored, Family-Based, Telehealth Intervention for Childhood Obesity

Adjuvant Avelumab in Merkel Cell Cancer

Communication About Sexual Health in Gynecologic Cancer

Somatostatin Analogues With Perioperative Antibiotics Versus Prolonged Antibiotics

RCT of CBT for Insomnia With PLWHA

Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control

Effectiveness of GSK598809, a Selective D3 Antagonist, Added to CBT and NRT for Smoking Cessation and Relapse Prevention

Shave Margins in Breast Conservation Therapy

A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes

Effect of 4-Hydroxytamoxifen Gel on Breast Density, Salivary Sex Steroids, and Quality of Life in Premenopausal Women

EASE Trial: Exhale Airway Stents for Emphysema

Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)

Living Longer and Stronger With Spinal Cord Injury (SCI)

Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults

A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism

Testing a Self-Management App for Symptoms of Posttraumatic Stress

Raising Healthy Children: A Hybrid Trial of the Family Check-Up 4 Health in Primary Care

Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial

A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety Disorder